leisure time -WSS

leisure time

author：explore 2025-09-27 12:57:00 - browse：31685

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Study: Hearing aids may slow cognitive decline in those at risk

Wikipedia

WSS

More hospitals are billing patients as online messages surge

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

A look at other Americans who have crossed into North Korea over the years

New menopause drug shows promise in relief for hot flashes

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

focus

leisure time

The next ALS data readout — overdue but important

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

New Medicare drug pricing powers could soon be upended in court

Psychedelics group wrestles with new pharma identity

Doulas covered by Medicaid under New York's new plan

Hepatitis C has a cure — but many Americans still lack access to it

Three issues to watch in global health in 2024

Medicare proposal to cover medical devices draws a mixed reaction

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Walensky prepares to leave CDC — and Congress — behind

How I ended up pumping milk in a bathroom stall at JPM 2024

Wikipedia

Heart disease and mental health: A look at cardiac psychology

What we know about the American soldier detained in North Korea

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Biden administration sends mixed signals on US soldier who crossed into North Korea

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Heart disease and mental health: A look at cardiac psychology

leisure time

entertainment

Wikipedia

hotspot